 |
200 Diseases |  |
189 Trials |
|
189 Trials |  |
19718 News |  |
| «12...165166167168169170171172173174175...202203» |
- Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie, azathioprine orodispersible / Generic Mfg.
OPTIMIZATION OF DOSES OF THIOPURINIC DRUGS (AZATIOPRINE AND MERCAPTOPURINE) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE UNDER TREATMENT COMBINED WITH ANTI-TNF ALPHA (INFLIXIMAB/ADALIMUMAB) (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_1675;
Consistent with the findings of other studies, there are no differences in the pharmacokinetic characteristics or in the responses of patients with the biologic treatment combined with thiopurine a standard dose with respect to the group with low dose (< 2 mg/kg). The use of a lower dose of Azathioprine can provide a better tolerance of the drug, a better safety profile, and lower economic cost.
- Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
HIGH PLATELET COUNT PREDICTS A RAPID RESPONSE TO ADALIMUMAB AND A FAVOURABLE SHORT-TERM OUTCOME IN PATIENTS WITH ULCERATIVE COLITIS: A MULTI-CENTRE RETROSPECTIVE COHORT STUDY (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_1672;
Up to an 80% of the rapid responders also achieved remission at 12 weeks. The rate of rapid response was significantly higher in patients with platelet count ≥312 × 109 /L.
- THERAPEUTIC INTENSIFICATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE - A COMPARISON OF DIFFERENT BIOLOGIC THERAPIES (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_1670;
This was a retrospective cohort single center study including patients under maintenance therapy with Infliximab (IFX), Adalimumab (ADA), Golimumab (GLB) or Vedolizumab (VDZ). Therapeutic intensification is more frequent and occurs earlier in patients with UC, regardless of the treatment used.
- Humira (adalimumab) / Eisai, AbbVie
ASSESSMENT OF PATIENTS' PREFERENCE FOR A NEW AUTO-INJECTION PEN COMPARED WITH THE PREFILLED SYRINGE FOR SELF-ADMINISTRATION OF ADALIMUMAB IN PATIENTS WITH CROHN'S DISEASE: A PROSPECTIVE COHORT STUDY (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_1657;
Further, approximately 70% of patients answered that the new pen was generally better than the syringe at the first self-injection. In addition, the proportion of patients who preferred the new pen was higher at the seventh self-injection than at the first self-injection.
- Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
LONG-TERM OUTCOMES OF INFLIXIMAB THERAPY FOR PATIENTS WITH CROHN'S DISEASE AT DIFFERENT TIMES OF INITIATION OF INFLIXIMAB ADMINISTRATION: A SINGLE-CENTRE COHORT STUDY IN JAPAN (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_1656;
The rates of dose escalation of infliximab and intestinal resection of patients with Crohn's disease who were administered infliximab after 2011 were lower than those of patients who were administered infliximab before 2010. Early induction of infliximab and a combined therapy with infliximab and immunomodulators in the 2011-2017 period may have contributed to the reduction in the rates of dose escalation of infliximab and intestinal resection.
- A MULTICENTRIC STUDY ON THE EFFECTIVENESS OF ANTI-TNF AGENTS IN SYMPTOMATIC STRICTURING CROHN'S DISEASE (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_1650;
One hundred-forty one patients (54%) received infliximab and 121 (46%) adalimumab. Anti-TNF agents are effective in approximately 20% of patients with Crohn's disease complicated with symptomatic strictures, avoiding surgery in a relatively high proportion of cases.
- LIVING WITH ULCERATIVE COLITIS IN GERMANY: EXPLORING CONCOMITANT STEROID AND IMMUNOSUPPRESSANT USE AMONG PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_1643;
Over a quarter of IM users were newly initiated on IM treatment following biologic initiation. These data suggest that control with biologic monotherapy is often insufficient treatment, highlighting the need for further advanced treatment options for this patient population.
- LIVING WITH ULCERATIVE COLITIS IN GERMANY: ESTIMATING THE FREQUENCY AND EXTENT OF DOSE ESCALATIONS AMONG PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_1642;
The prevalence and timing of dose escalations differed significantly between biologic therapies, with the largest proportion of dose escalations observed for ADA. These data suggest that many patients may require dose escalations to achieve and maintain remission when being treated with current biologic therapies.
- Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
PRELIMINARY ANALYSIS OF UTILISATION AND CLINICAL RESULTS FROM THE NHS SCOTLAND THERAPEUTIC DRUG MONITORING SERVICE FOR BIOLOGIC MEDICINES (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_1640;
It is estimated that > 50% of individuals treated with IFX or ADL have been tested at least once in the first year. DL results were found to be similar to previously published data, as were rates of antibody positivity.
- SUBOPTIMAL ADHERENCE TO VACCINATION IN PREGNANT PATIENTS WITH INFLAMMATORY BOWEL DISEASE ON BIOLOGICS (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_1632;
These results will serve as a starting point for establishing determinants of suboptimal adherence within the studied population. Ultimately, targeted education programs can be developed.
- Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
OPPORTUNISTIC INFECTION IN PATIENTS WITH INFLAMMATORY DISEASE USING BIOLOGICAL THERAPY. (PROSPECTIVE STUDY) (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_1623;
Patients undergoing biological therapy are more susceptible to becoming infected with clostridium, and not only those hospitalised or receiving antibiotics. This study points to the importance of clostridium research in this specific group of patients.
- Humira (adalimumab) / Eisai, AbbVie
USEFULNESS OF SERUM LEUCINE-RICH ALPHA-2-GLYCOPROTEIN (LRG) FOR MONITORING THE EFFICACY OF ADALIMUMAB TREATMENT IN PATIENTS WITH CROHN'S DISEASE (PLANET STUDY) (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_1618;
LRG is a novel serum biomarker for CD, which specially represents endoscopic activity of the disease. LRG may be superior to CRP and fCP for monitoring CD under adalimumab treatment.
- Humira (adalimumab) / Eisai, AbbVie
USEFULNESS OF LEUCINE-RICH ALPHA-2-GLYCOPROTEIN (LRG) TO MONITOR THE EFFICACY OF ADALIMUMAB TREATMENT IN PATIENTS WITH ULCERATIVE COLITIS (PLANET STUDY) (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_1613;
LRG may be superior to CRP and fCP for monitoring CD under adalimumab treatment. LRG is a novel serum biomarker which can reflect disease activity possibly better than CRP and fCP in UC patients with adalimumab treatment.
- Entyvio (vedolizumab) / Takeda, Humira (adalimumab) / Eisai, AbbVie
INTERLEUKINS LEVELS: ARE WE ON THE ROAD TO TAILORED THERAPY IN INFLAMMATORY BOWEL DISEASE? (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_1605;
IFN-g and TGF-b1 may be useful to identify AZA responders and IL8 and IL6 levels could be good predictors of response to both biological and immunosuppressive drugs. Our study is a first step for tailored therapy in IBD patients.
- Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
INADEQUATE FERTILITY AND PREGNANCY KNOWLEDGE IS RELATED TO VOLUNTARY CHILDLESSNESS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN SERBIA-RESULTS FROM TWO REFERRAL CENTERS (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_1597;
The CCPKnow score is extremely low in the examined population and is not related to the decision to have children after IBD diagnosis. Patients who had children after IBD was diagnosed were significantly younger at diagnosis and had more children than those who remained childless after IBD was diagnosed.
- Humira (adalimumab) / Eisai, AbbVie
TIME TRENDS OF CROHN´S DISEASE IN CATALONIA FROM 2011 TO 2017. INCREASING USE OF BIOLOGICS CORRELATES WITH A DECREASE IN SURGICAL REQUIREMENTS. A POPULATION-BASED STUDY IN CATALONIA (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_1593;
Use of biological drugs increased from 15.0% to 18.7% from 2011 to 2017. During the same periods we observed an improvement in the outcomes of CD patients.
- EFFECTS OF MATRIX METALLOPROTEINASE (MMP)-7, MMP-13 AND CATHEPSIN G ON THE INTEGRITY AND FUNCTION OF ANTI-TUMOUR NECROSIS FACTOR (TNF)-α AND ANTI-INTEGRIN BIOLOGIC AGENTS (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_1587;
Despite being known to cleave immunoglobulins,2 MMP-7 and MMP-13 do not appear to impair the integrity and function of Infliximab and Adalimumab. In keeping with our previous findings, Etanercept appears to be highly susceptible to the action of proteases.
- Stelara (ustekinumab) / J&J, Humira (adalimumab) / Eisai, AbbVie
HIGH SEROCONVERSION RATE TO TRIVALENT INFLUENZA VACCINE DURING USTEKINUMAB TREATMENT IN CROHN'S DISEASE: RESULTS FROM A PROSPECTIVE COHORT STUDY (A2) - Aug 18, 2019 - Abstract #UEGW2019UEGW_1205;
Seroconversion rate to the seasonal trivalent influenza vaccination during ustekinumab treatment in CD patients is high, in contrast to the reduced rate observed for adalimumab. Patients treated with ustekinumab can be effectively vaccinated with the trivalent influenza vaccine.
- REAL-WORLD SAFETY OF VEDOLIZUMAB AND ANTI-TNF THERAPIES IN BIOLOGIC-NAÏVE ULCERATIVE COLITIS AND CROHN'S DISEASE PATIENTS: RESULTS FROM THE EVOLVE STUDY (A2) - Aug 18, 2019 - Abstract #UEGW2019UEGW_1202;
Bio-naïve pts treated with VDZ had a significantly lower likelihood of experiencing SAEs and SIs, including GI infections, than those treated with anti-TNF therapies. These data support a favourable safety profile of VDZ versus anti-TNF in bio-naïve inflammatory bowel disease pts in real-world clinical practice.
- Stelara (ustekinumab) / J&J, Entyvio (vedolizumab) / Takeda, Humira (adalimumab) / Eisai, AbbVie
Treatment aims of therapeutic drug monitoring (C3) - Aug 18, 2019 - Abstract #UEGW2019UEGW_24;
In the recent pediatric PAILOT trial, a proactive dose-adjustment of adalimumab based on TDM and inflammatory markers was superior to conventional therapy for improving long-term outcomes of CD patients. More trials on 'proactive TDM' are eagerly awaited.
- || Humira (adalimumab) / Eisai, AbbVie
If you're filming a commercial and the guy is supposed to be painting a wall, it's a lot more realistic if the paintbrush has paint on it. #humira @abbvie (Twitter) - Aug 18, 2019
- | Humira (adalimumab) / Eisai, AbbVie
Journal: Successful Treatment of Refractory Juvenile Dermatomyositis With Adalimumab. (Pubmed Central) - Aug 17, 2019
More trials on 'proactive TDM' are eagerly awaited. No abstract available
- | Humira (adalimumab) / Eisai, AbbVie
Journal: Prolonged Persistence of Adalimumab Transferred From Mother to Infant During Pregnancy. (Pubmed Central) - Aug 17, 2019
No abstract available No abstract available
- | Entyvio (vedolizumab) / Takeda, Humira (adalimumab) / Eisai, AbbVie
Journal: Chronic granulomatous disease as a rare differential diagnosis of inflammatory bowel disease (Pubmed Central) - Aug 17, 2019
In light of recent literature, this case report shows that chronic granulomatous disease should be considered as a differential diagnosis to therapy refractory IBD. This is the case, especially in young patients, when recurrent bacterial lesions caused by intestine-atypical pathogens appear.
- | Retrospective data, Review, Journal, HEOR: Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluation. (Pubmed Central) - Aug 16, 2019
Compared with vedolizumab, tofacitinib was associated with a similar number of QALYs, at a lower cost. Tofacitinib is an efficacious treatment for moderately to severely active ulcerative colitis and is likely to be a cost-effective use of NHS resources.
- ||| upadacitinib (ABT-494) / AbbVie, Humira (adalimumab) / Eisai, AbbVie
Clinical: Lucky timing! Just put up an episode on SELECT-COMPARE (upadacitinib vs. adalimumab vs. placebo). https://t.co/yJyG1nlVvF Why the VTE warning? Have not seen evidence of that in the trials yet. Assuming concerns about class effect? (Twitter) - Aug 16, 2019
- || Humira (adalimumab) / Eisai, AbbVie
AbbVie scores blockbuster approval for RA med Rinvoq, its crucial Humira followup https://t.co/91ErPRLGlB (Twitter) - Aug 16, 2019
- ||| Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
@IBD_Afzali - Perhaps just remember the magic number 10 for Adalimumab and Infliximab as good therapeutic level #ibdschool #acgregional19 (Twitter) - Aug 16, 2019
- ||| Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
Reimbursement: In addition to my comments above about why Humira won’t work after primary non-response to infliximab, Entocort is not approved to treat #UC and there are not data for it in this situation. If you can, call your state insurance commissioner. (Twitter) - Aug 15, 2019
- | Humira (adalimumab) / Eisai, AbbVie
Biomarker, Clinical, Journal: Effect of 2 Psoriasis Treatments on Vascular Inflammation and Novel Inflammatory Cardiovascular Biomarkers: A Randomized Placebo-Controlled Trial. (Pubmed Central) - Aug 15, 2019
P4
Glycoprotein acetylation improvement may partially explain the beneficial effects of adalimumab seen in observational studies. Larger studies with more detailed phenotyping of vascular disease should assess the comparative differences in the effects of adalimumab and phototherapy seen in our study.
- || Xeljanz (tofacitinib) / Pfizer, Humira (adalimumab) / Eisai, AbbVie
UC pt here experiencing same: PNR to IFX, no response to vedo, BCBS will not approve #Xeljanz without 12-week trial of Humira first. Also will not approve #Uceris w/o failing Entocort within last 90 days. Afraid I will lose colon before getting meds that work. (Twitter) - Aug 15, 2019
- | Humira (adalimumab) / Eisai, AbbVie, Cosentyx (secukinumab) / Novartis
Journal: Pyoderma gangrenosum triggered by switching from adalimumab to secukinumab. (Pubmed Central) - Aug 15, 2019
Larger studies with more detailed phenotyping of vascular disease should assess the comparative differences in the effects of adalimumab and phototherapy seen in our study. No abstract available
- | Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: Early Predictors of the Long-term Response to Therapy in Patients With Crohn Disease Derived From a Time-Intensity Curve Analysis After Microbubble Contrast Agent Injection. (Pubmed Central) - Aug 15, 2019
No abstract available The analysis of time-intensity curves obtained after microbubble contrast agent injection provides early predictors of the long-term therapeutic outcome in patients with CD.
- | Humira SC (adalimumab/hyaluronidase) / AbbVie, Xeljanz (tofacitinib) / Pfizer, Humira (adalimumab) / Eisai, AbbVie
Journal: Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease. (Pubmed Central) - Aug 15, 2019
P3
The analysis of time-intensity curves obtained after microbubble contrast agent injection provides early predictors of the long-term therapeutic outcome in patients with CD. This analysis suggests that disease-specific composite measures are appropriate for evaluating treatment efficacy on multiple disease domains in PsA.
- | Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
Clinical, Retrospective data, Journal: Timing of infliximab and adalimumab initiation despite methotrexate in children with chronic non-infectious anterior uveitis. (Pubmed Central) - Aug 15, 2019
Children with idiopathic CAU and males required TNFi earlier in their course. Factors associated with these potential risk factors for TNFi warrant further investigation.
- | Remicade (infliximab) / Mitsubishi Tanabe, J&J, Enbrel (etanercept) / Takeda, Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
Journal: Application of TNF-alpha inhibitors in treatment of uveitis associated with ankylosing spondylitis (Pubmed Central) - Aug 15, 2019
The review features theoretical prerequisites for application of tumor necrosis factor alpha (TNF-alpha) inhibitors: infliximab, adalimumab and etanercept. Literature data speaks for high efficacy of TNF-alpha inhibitors in prevention and arrest of uveitis onset in patients with AS.
- | Humira (adalimumab) / Eisai, AbbVie
Top 10 all-star drugs in 2024: Humira's captain, but who else makes the roster? https://t.co/j786JVZ1tg (Twitter) - Aug 15, 2019
- ||| Humira (adalimumab) / Eisai, AbbVie
Clinical: Please understand that this step policy is medically incorrect and will cost @TeamShieldBSC more money. Humira will NOT work after primary mechanism failure of inflix. Oh, and yes btw the patient will get sicker. ➡️DM me if you want me to teach your team (gratis). #fightwithus (Twitter) - Aug 14, 2019
- |||| Humira (adalimumab) / Eisai, AbbVie
Reimbursement: As you state indirectly, Humira inappropriate here. Another of many examples of #insurancemalpractice in the #IBD space (Twitter) - Aug 14, 2019
- ||| Humira (adalimumab) / Eisai, AbbVie
Clinical: Via @IMAKglobal: Drugmaker @abbvie filed 247 patent applications on Humira in 2017. #BigPharma’s abusive practices must be stopped. (Twitter) - Aug 14, 2019
- |||| Stelara (ustekinumab) / J&J, Humira (adalimumab) / Eisai, AbbVie
Clinical: 21 yo F w longstanding SB/colonic Crohn's, failing IFX despite trough 15.4, recent 5 lb weight loss (BMI 14.8), hospitalized with abd pain. @blueshieldCA denies Stelara due to policy requiring failing Humira first. Won't even honor peer-to-peer request. @IBDMD #fightwithme (Twitter) - Aug 14, 2019
- | Humira (adalimumab) / AbbVie
Trial completion date, Trial initiation date, Monotherapy: CoCroS: Control Crohn Safe Trial (clinicaltrials.gov) - Aug 14, 2019
P4, N=158, Not yet recruiting, Sponsor: Maastricht University Medical Center
Literature data speaks for high efficacy of TNF-alpha inhibitors in prevention and arrest of uveitis onset in patients with AS. Trial completion date: May 2023 --> Sep 2023 | Initiation date: May 2019 --> Sep 2019
- | Humira (adalimumab) / Eisai, AbbVie
theres a Humira ad that shows a young girl bring her boyfriend to meet her parents / every pharma ad is a fraud !! (Twitter) - Aug 12, 2019
- | Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: Leukocytoclastic vasculitis complicating adalimumab therapy for Crohn's disease: Report of three cases. (Pubmed Central) - Aug 11, 2019
Trial completion date: May 2023 --> Sep 2023 | Initiation date: May 2019 --> Sep 2019 No abstract available
- | Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal, Monotherapy: Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate. (Pubmed Central) - Aug 11, 2019
P3, P4
The addition of adalimumab at 6 months after methotrexate failure is associated with improved outcomes. These results support treatment-to-target strategies and timely adaptation of therapy in patients with early RA.
- | Humira (adalimumab) / Eisai, AbbVie
Trial completion, Trial completion date, Trial primary completion date: Post-Marketing Surveillance Study of Adalimumab in Pediatric Chronic Severe Plaque Psoriasis Patients in Korea (clinicaltrials.gov) - Aug 9, 2019
P=N/A, N=2, Completed, Sponsor: AbbVie
These results support treatment-to-target strategies and timely adaptation of therapy in patients with early RA. Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Jul 2019 | Trial primary completion date: Dec 2019 --> Jul 2019
- | Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
Clinical, Retrospective data, Journal: Efficacy and Safety of Adalimumab in Pediatric Ulcerative Colitis: A Real-life Experience from the SIGENP-IBD Registry. (Pubmed Central) - Aug 9, 2019
Based on our data, ADA seems to be effective in children with UC, allowing to recover a significant percentage of patients intolerant or not-responding to IFX. The safety profile was good.
- | Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: Efficacy and safety of Adalimumab after failure of other anti-TNFα agents for plaque-type psoriasis: clinician behaviour in real life clinical practice. (Pubmed Central) - Aug 8, 2019
The safety profile was good. Adalimumab profile was excellent in this 5-years retrospective observation, showing the clinical validity of interclass transitioning among anti-TNFα options.
- | Humira (adalimumab) / Eisai, AbbVie, Cimzia (certolizumab pegol) / Astellas, Dermira, UCB
Clinical, Journal: Defining an Optimal Adherence Threshold for Patients Taking Subcutaneous Anti-TNFs for Inflammatory Bowel Diseases. (Pubmed Central) - Aug 8, 2019
Patients who delay refills >2 days on average every 2 weeks of their subcutaneous biologics have significantly increased risk of flare. Further studies to improve adherence among those patients who consistently delay medication use are necessary.Am J Gastroenterol advance online publication, 12 December 2017; doi:10.1038/ajg.2017.438.